# reload+after+2024-01-21 03:48:04.128800
address1§828 Winter Street
address2§Suite 300
city§Waltham
state§MA
zip§02451
country§United States
phone§857 524 2466
website§https://xiliotx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
fullTimeEmployees§81
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Rene  Russo BCPS, Pharm.D.', 'age': 48, 'title': 'President, CEO & Director', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 888493, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin M. Brennan', 'age': 53, 'title': 'Senior VP of Finance & Accounting', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher  Frankenfield', 'title': 'Chief Operating Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Uli  Bialucha Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Julissa  Viana', 'title': 'Vice President of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Stacey J. Davis', 'title': 'Chief Business Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Katarina  Luptakova M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Scott  Coleman Ph.D.', 'title': 'Chief Development Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.425
currency§USD
dateShortInterest§1702598400
forwardEps§-3.1
exchange§NMS
quoteType§EQUITY
shortName§Xilio Therapeutics, Inc.
longName§Xilio Therapeutics, Inc.
firstTradeDateEpochUtc§1634909400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a29df73e-2ef5-3eed-8f1d-9d3cdeb4d4fb
gmtOffSetMilliseconds§-18000000
targetHighPrice§6.0
targetLowPrice§5.0
targetMeanPrice§5.5
targetMedianPrice§5.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§3.531
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
